» Articles » PMID: 35862394

Epigenetic and Transcriptome Responsiveness to ER Modulation by Tissue Selective Estrogen Complexes in Breast Epithelial and Breast Cancer Cells

Overview
Journal PLoS One
Date 2022 Jul 21
PMID 35862394
Authors
Affiliations
Soon will be listed here.
Abstract

Selective estrogen receptor modulators (SERMs), including the SERM/SERD bazedoxifene (BZA), are used to treat postmenopausal osteoporosis and may reduce breast cancer (BCa) risk. One of the most persistent unresolved questions regarding menopausal hormone therapy is compromised control of proliferation and phenotype because of short- or long-term administration of mixed-function estrogen receptor (ER) ligands. To gain insight into epigenetic effectors of the transcriptomes of hormone and BZA-treated BCa cells, we evaluated a panel of histone modifications. The impact of short-term hormone treatment and BZA on gene expression and genome-wide epigenetic profiles was examined in ERαneg mammary epithelial cells (MCF10A) and ERα+ luminal breast cancer cells (MCF7). We tested individual components and combinations of 17β-estradiol (E2), estrogen compounds (EC10) and BZA. RNA-seq for gene expression and ChIP-seq for active (H3K4me3, H3K4ac, H3K27ac) and repressive (H3K27me3) histone modifications were performed. Our results show that the combination of BZA with E2 or EC10 reduces estrogen-mediated patterns of histone modifications and gene expression in MCF-7ERα+ cells. In contrast, BZA has minimal effects on these parameters in MCF10A mammary epithelial cells. BZA-induced changes in histone modifications in MCF7 cells are characterized by altered H3K4ac patterns, with changes at distal enhancers of ERα-target genes and at promoters of non-ERα bound proliferation-related genes. Notably, the ERα target gene GREB1 is the most sensitive to BZA treatment. Our findings provide direct mechanistic-based evidence that BZA induces epigenetic changes in E2 and EC10 mediated control of ERα regulatory programs to target distinctive proliferation gene pathways that restrain the potential for breast cancer development.

Citing Articles

H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer.

Xiao C, Ren Y, Chen Q, Yang Y, Tang L, Xu L Epigenetics. 2024; 19(1):2343593.

PMID: 38643489 PMC: 11037280. DOI: 10.1080/15592294.2024.2343593.


The 100 top-cited articles in menopausal syndrome: a bibliometric analysis.

Jin Z, Tian C, Kang M, Hu S, Zhao L, Zhang W Reprod Health. 2024; 21(1):47.

PMID: 38589898 PMC: 11003046. DOI: 10.1186/s12978-024-01770-9.

References
1.
Mirkin S, Pickar J . Selective estrogen receptor modulators (SERMs): a review of clinical data. Maturitas. 2014; 80(1):52-7. DOI: 10.1016/j.maturitas.2014.10.010. View

2.
Wardell S, Ellis M, Alley H, Eisele K, VanArsdale T, Dann S . Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. Clin Cancer Res. 2015; 21(22):5121-5130. PMC: 4644714. DOI: 10.1158/1078-0432.CCR-15-0360. View

3.
Guillemette B, Drogaris P, Lin H, Armstrong H, Hiragami-Hamada K, Imhof A . H3 lysine 4 is acetylated at active gene promoters and is regulated by H3 lysine 4 methylation. PLoS Genet. 2011; 7(3):e1001354. PMC: 3069113. DOI: 10.1371/journal.pgen.1001354. View

4.
Lun A, Smyth G . csaw: a Bioconductor package for differential binding analysis of ChIP-seq data using sliding windows. Nucleic Acids Res. 2015; 44(5):e45. PMC: 4797262. DOI: 10.1093/nar/gkv1191. View

5.
Stender J, Kim K, Charn T, Komm B, Chang K, Kraus W . Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol. 2010; 30(16):3943-55. PMC: 2916448. DOI: 10.1128/MCB.00118-10. View